Please ensure Javascript is enabled for purposes of website accessibility

Why Novavax, Inc. Stock Blasted Off in January

By George Budwell - Feb 4, 2018 at 4:49PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Novavax shined in January, but February may be even better for this small-cap biotech stock.

What happened

Novavax (NVAX -5.13%), a clinical-stage vaccine company, saw its shares crush the broader markets last month. Specifically, the biotech's shares gained an astounding 61.4% in January, according to S&P Global Market Intelligence 

The catalyst? The biotech's shares are apparently benefiting from the news that the current cohort of FDA-approved flu vaccines from GlaxoSmithKline (GSK -0.80%) and Sanofi (SNY -0.88%) have largely failed to curtail the ongoing epidemic. The Centers for Disease Control, after all, recently deemed this season to be one of the most severe, and deadly, in over a decade.  

Man wrapped in a blanket sitting on a sofa, holding a tissue over his nose, apparently suffering from the flu.

Image source: Getty Images.

So what

Novavax is on track to release early-stage data for its flu vaccine candidate, NanoFlu, this month. These preliminary data are unlikely to be enough to warrant an accelerated approval from regulators, but they may spark a buyout offer from the current market share leaders Glaxo and Sanofi. 

Now what

It's no secret that Sanofi is on an acquisition binge right now. The French drugmaker, after all, needs to find new sources of revenue to push beyond the patent expiration of its flagship diabetes product, Lantus.

In the same breath, Glaxo is also reportedly gearing up to start making acquisitions of its own in an effort to return to modest levels of top-line growth sometime in the near future. As such, Sanofi and Glaxo appear to be logical suitors for Novavax in the event that NanoFlu proves to be efficacious and safe in human beings. These two top drugmakers have robust vaccine portfolios that would dovetail nicely with Novavax's current clinical lineup.  

That being said, the current buyout speculation surrounding Novavax is simply not a good reason to buy its stock. A buyout may happen soon. But the more likely scenario is for potential suitors to wait until NanoFlu has proved its worth in a pivotal-stage trial. Therefore, investors should arguably base their buy -- or sell -- decisions solely on Novavax's prospects in the clinic. Everything else will take care of itself, after all. 

 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax, Inc. Stock Quote
Novavax, Inc.
NVAX
$51.06 (-5.13%) $-2.76
Sanofi Stock Quote
Sanofi
SNY
$52.14 (-0.88%) $0.46
GSK Stock Quote
GSK
GSK
$43.35 (-0.80%) $0.35

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
332%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.